cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Company profile
Ticker
CLLS
Exchange
Website
CEO
Andre Choulika
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CLLS stock data
Latest filings (excl ownership)
6-K
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
22 Apr 24
6-K
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
10 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
16 Jan 24
6-K
Current report (foreign)
22 Dec 23
6-K
Current report (foreign)
22 Dec 23
6-K
Current report (foreign)
5 Dec 23
6-K
Current report (foreign)
17 Nov 23
6-K
Current report (foreign)
17 Nov 23
6-K
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
15 Nov 23
Transcripts
CLLS
Earnings call transcript
2022 Q3
4 Nov 22
CLLS
Earnings call transcript
2022 Q2
5 Aug 22
CLLS
Earnings call transcript
2022 Q1
13 May 22
CLLS
Earnings call transcript
2021 Q4
4 Mar 22
CLLS
Earnings call transcript
2021 Q3
5 Nov 21
CLLS
Earnings call transcript
2021 Q2
6 Aug 21
CLLS
Earnings call transcript
2020 Q3
6 Nov 20
Latest ownership filings
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G/A
PFIZER INC
14 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
5 Dec 23
SC 13D/A
ASTRAZENECA PLC
16 Nov 23
SC 13D/A
Bpifrance Participations SA
13 Nov 23
SC 13D
ASTRAZENECA PLC
9 Nov 23
SC 13D/A
Cibus, Inc.
1 Jun 23
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 23
SC 13D/A
Bpifrance Participations SA
14 Feb 23
SC 13G/A
BAILLIE GIFFORD & CO
18 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
25.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 17.90 bn |
Total shares | 17.91 mm |
Total puts | 800.00 |
Total calls | 3.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Bpifrance Participations | 6.43 mm | $15.30 mm |
Long Focus Capital Management | 4.49 mm | $7.09 bn |
Capital International Investors | 1.85 mm | $2.92 bn |
Credit Suisse | 1.44 mm | $2.27 bn |
Baillie Gifford & Co | 1.16 mm | $1.84 bn |
Millennium Management | 1.10 mm | $1.73 bn |
PFG Principal Financial Group Inc - Registered Shares | 656.60 k | $1.04 bn |
MCQEF Macquarie | 226.88 k | $358.00 mm |
KBCSF KBC | 163.45 k | $0.00 |
Oppenheimer & Co | 121.42 k | $191.84 mm |